Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Takeda Zeros in on US Successor Ahead of 2026 CEO Transition
Takeda Pharmaceutical is intensifying efforts to identify a new leader for its US business as the company gears up for the transition of CEO Christophe Weber’s role to Julie Kim in June 2026. Speaking at the annual general meeting on…
To read the full story
Related Article
- Takeda Rejigs Structure Ahead of CEO Transition, Creates New International Unit
January 30, 2026
- Julie Kim Tapped to Take Over Helm of Takeda in 2026
January 31, 2025
BUSINESS
- Sumitomo Pharma Sees iPSC Therapy as Potential US$1 Billion Global Product
February 18, 2026
- AstraZeneca Launches Japan Registry Study of Imfinzi in Limited-Stage SCLC
February 18, 2026
- Asahi Kasei Gets Global Rights to Alchemedicine’s Lead Compounds
February 18, 2026
- Teijin, ASKA Hook Up on Gynecology Drug Discovery
February 18, 2026
- Fycompa Generics Approved despite Extended Patent, Hydrate Switch in Play?
February 17, 2026
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…